Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Uveitis

Sterile Intraocular Inflammation Associated With Faricimab

JAMA Ophthalmol

Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA

doi: 10.1001/jamaophthalmol.2024.3828

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular DiseasesFurther Publications

Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients

Am J Ophthalmol

Ghezala IB, Gabrielle PH, Sibert M, Steinberg LA, Dautriche A, Arnould L, Creuzot-Garcher C

doi: 10.1016/j.ajo.2024.08.008

Further Publications

Drugs Associated with Floppy Iris Syndrome: A Real-World Population-Based Study: Drugs Associated with Floppy Iris Syndrome

Am J Ophthalmol

Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Hurley B, Muni RH

doi: 10.1016/j.ajo.2025.03.023

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Further Publications

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy

JAMA Ophthalmol

Yu-Wai-Man P, Newman NJ, Biousse V, Carelli V, Moster ML, Vignal-Clermont C, Klopstock T, Sadun AA, Sergott RC, Hage R, Degli Esposti S, La Morgia C, Priglinger C, Karanja R, Taiel M, Sahel JA, LHON Study Group

doi: 10.1001/jamaophthalmol.2024.5375

Glaucoma and Ocular Pressure

Human Papillomavirus Infection is Associated with Increased Risk of Glaucoma: Real-World Evidence

Ophthalmology

Liao WC, Su YJ, Li YF, Lo SW, Lee CY, Chang HC, Gau SY

doi: 10.1016/j.ophtha.2025.05.019

Related content

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Sterile Intraocular Inflammation Associated With Faricimab

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients

Drugs Associated with Floppy Iris Syndrome: A Real-World Population-Based Study: Drugs Associated with Floppy Iris Syndrome

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy

Human Papillomavirus Infection is Associated with Increased Risk of Glaucoma: Real-World Evidence